心肌梗死后心律失常监测的临床效果(BIO-GUARD|MI):一项随机对照试验的研究方案
BIO-GUARD-MI研究为随机对照试验,计划纳入约1400例CHA2DS2-VASc评分≥4且左心室射血分数>35%的心梗后高危患者,随机分入植入式心脏监测器(ICM)组或常规治疗组,随访至发生372个主要终点事件,旨在探讨通过ICM早期发现并治疗心律失常能否降低主要不良心脏事件发生率。
要点
- ICM可早期记录无症状心律失常,远程监测使医生能早期预警新发心律失常。
- 既往试验显示心梗后发生房颤、心动过缓、室性心动过速等心律失常的患者主要不良心脏事件风险增加。
- BIO-GUARD-MI旨在验证ICM早期发现并治疗心律失常能否降低主要不良心脏事件发生率。
核心结论
- BIO-GUARD-MI试验旨在研究通过ICM早期发现并治疗心肌梗死后患者的心律失常能否降低主要不良心脏事件的发生率。
- 该试验是首次尝试简化对心律失常复杂性质的应对。
研究设计与样本
- BIO-GUARD-MI为随机对照试验,计划纳入CHA2DS2-VASc评分≥4且左心室射血分数>35%的心梗后高危患者,随机分配至ICM组或常规治疗组。
- 计划纳入约1400例患者,随访至发生372个主要终点事件。
- 医生会收到关于如何应对ICM记录到的心律失常的建议。
主要发现
- 既往使用ICM对心梗后心律失常进行连续心电监测的试验显示,发生房颤、心动过缓及室性心动过速等心律失常的患者主要不良心脏事件风险增加。
关键数值与推荐
- 纳入标准为CHA2DS2-VASc评分≥4且左心室射血分数>35%的心梗后患者。
- 主要终点为发生372个主要终点事件。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The increasing use of implantable cardiac monitors (ICMs) allows early documentation of asymptomatic cardiac arrhythmias that would previously have gone unnoticed. The addition of remote monitoring to cardiac devices means that physicians receive an early warning in cases of new-onset arrhythmias. While remote monitoring has been suggested to increase survival in heart failure patients with implantable defibrillators, trials using ICMs for continuous electrocardiographic monitoring of cardiac arrhythmias in the postmyocardial infarction setting have shown that patients who experienced cardiac arrhythmias such as atrial fibrillation, bradycardia, and ventricular tachyarrhythmia have an increased risk of major adverse cardiac events. METHODS: The Biomonitoring in patients with preserved left ventricular function after diagnosed myocardial infarction (BIO-GUARD-MI) study is designed to investigate and clarify whether the incidence of major adverse cardiac events can be decreased by early detection and treatment of cardiac arrhythmias using an ICM in patients after myocardial infarction. In addition, the study will allow us to describe the interplay between baseline characteristics, arrhythmias, and clinical events to improve the treatment of this high-risk patient population. The study will enroll and randomize a cohort of high-risk postmyocardial infarction patients with CHA2DS2-VASc score ≥ 4 and left ventricular ejection fraction > 35% to an ICM or conventional treatment. Physicians are provided with suggestions on how to respond to ICM-documented arrhythmias. An estimated 1400 patients will be enrolled and followed until 372 primary endpoints have occurred. In this paper, we describe the literature and rationale behind the design and interventions towards new-onset arrhythmias, as well as future perspectives and limitations for the use of ICMs. DISCUSSION: Remote monitoring may improve clinical outcome if it uncovers conditions with low symptom burden which cause or indicate an increased risk. A simple and easily implementable response to the information is important. Cardiac arrhythmias frequently start as asymptomatic, shorter lasting, and nightly events. The BIO-GUARD-MI trial represents the first attempt to simplify the response to the rather complex nature of heart arrhythmias. TRIAL REGISTRATION: Clinical Trials, NCT02341534 . Registered on 19 January 2015.
引用
- Jons C, Sogaard P, Behrens S, et al. The clinical effect of arrhythmia monitoring after myocardial infarction (BIO-GUARD|MI):study protocol for a randomized controlled trial. Trials. 2019. PMID: 31511057. doi:10.1186/s13063-019-3644-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。